A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Hill, Richard ^a   Kalathur, Ravi Kiran Reddy ^a   Callejas, Sergio ^b   Colaço, Laura ^a   Brandão, Ricardo ^a   Serelde, Beatriz ^c   Cebriá, Antonio ^c   Blanco Aparicio, Carmen ^c   Pastor, Joaquín ^c   Futschik, Matthias ^a   Dopazo, Ana ^b   Link, Wolfgang ^a  

^a UNIVERSITY OF ALGARVE   (Portugal)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ETP 45658; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANALYSIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL INVASION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SIGNALING ASSAY; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; COMPUTER MODEL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG POTENCY; DRUG SOLUBILITY; EC50; ENZYME ACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; GENE EXPRESSION; GENE SET ENRICHMENT ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MICROARRAY ANALYSIS; OSTEOSARCOMA CELL LINE; PHENOTYPE; PHYSICAL CHEMISTRY; PROMOTER REGION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL CYCLE CHECKPOINT; COMPUTER SIMULATION; DRUG EFFECTS; FEMALE; HCT116 CELL LINE; MCF 7 CELL LINE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HCT116 CELLS; HUMANS; IN VITRO TECHNIQUES; MCF-7 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84924280352     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0482-y     Document Type: Article

References (63)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091.
3. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008, 8:187-198.
4. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD: Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001, 70:535-602.
5. Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
6. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
7. Zhao L, Vogt PK: Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.
8. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 1998, 95:13513-13518.
9. Workman P, Clarke PA, Raynaud FI, van Montfort RL: Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010, 70:2146-2157.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-53.
11. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
12. Courtney KD, Corcoran RB, Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
13. Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921-929.
14. Furuyama T, Nakazawa T, Nakano I, Mori N: Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J 2000, 349:629-634.
15. Xuan Z, Zhang MQ: From worm to human: bioinformatics approaches to identify FOXO target genes. Mech Ageing Dev 2005, 126:209-215.
16. Zanella F, Link W, Carnero A: Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets 2010, 10:135-146.
17. Link W, Oyarzabal J, Serelde BG, Albarran MI, Rabal O, Cebria A, Alfonso P, Fominaya J, Renner O, Peregrina S, Soilán D, Ceballos PA, Hernández AI, Lorenzo M, Pevarello P, Granda TG, Kurz G, Carnero A, Bischoff JR: Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem 2009, 284:28392-28400.
18. ProQinase GmbH, Freiburg, Germany [http://www.proquinase.com ]
19. The R Project for Statistical Computing [http://www.r-project.org/ ]
20. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
21. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
22. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, Assa S, Karp M, Benjamini Y, Hochberg Y, Laron Z: Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995, 45:486-490.
23. Kalathur RK, Hernandez-Prieto MA, Futschik ME: Huntington's disease and its therapeutic target genes: a global functional profile based on the HD Research Crossroads database. BMC Neurol 2012, 12:47.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
25. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S: AmiGO: online access to ontology and annotation data. Bioinformatics 2009, 25:288-289.
26. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M: Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014, 42:D199-D205.
27. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP: Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011, 27:1739-1740.
28. Hill R, Madureira PA, Waisman DM, Lee PW: DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. Oncotarget 2011, 2:1094-1108.
29. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46:3-26.
31. Zanella F, Dos Santos NR, Link W: Moving to the core: spatiotemporal analysis of Forkhead box O (FOXO) and nuclear factor-kappaB (NF-kappaB) nuclear translocation. Traffic 2013, 14:247-258.
32. Mayo LD, Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001, 98:11598-11603.
33. Basu S, Totty NF, Irwin MS, Sudol M, Downward J: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003, 11:11-23.
34. Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90.
35. Grimes CA, Jope RS: CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 2001, 78:1219-1232.
36. Du K, Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998, 273:32377-32379.
37. Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR: Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 1994, 9:59-70.
38. Lutterbach B, Hann SR: Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994, 14:5510-5522.
39. Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, Karin M, Hunter T: Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991, 64:573-584.
40. Eijkelenboom A, Mokry M, De WE, Smits LM, Polderman PE, Van Triest MH, Van BR, Schulze A, De LW, Cuppen E, Burgering BM: Genome-wide analysis of FOXO3 mediated transcription regulation through RNA polymerase II profiling. Mol Syst Biol 2013, 9:638.
41. Greer EL, Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24:7410-7425.
42. Terragni J, Graham JR, Adams KW, Schaffer ME, Tullai JW, Cooper GM: Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors. BMC Cell Biol 2008, 9:6.
43. Geng T, Li P, Yin X, Yan Z: PGC-1alpha promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. Am J Pathol 2011, 178:1738-1748.
44. Martinez-Gac L, Marques M, Garcia Z, Campanero MR, Carrera AC: Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol 2004, 24:2181-2189.
45. Arden KC: FoxO: linking new signaling pathways. Mol Cell 2004, 14:416-418.
46. Accili D, Arden KC: FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004, 117:421-426.
47. Tinkum KL, White LS, Marpegan L, Herzog E, Piwnica-Worms D, Piwnica-Worms H: Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice. J Biol Chem 2013, 288:27999-28008.
48. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
49. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64:7678-7681.
50. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004, 3:772-775.
51. Collins I, Workman P: New approaches to molecular cancer therapeutics. Nat Chem Biol 2006, 2:689-700.
52. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
53. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004, 166:213-223.
54. Carracedo A, Pandolfi PP: The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
55. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, De Haven BA, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007, 67:5840-5850.
56. Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerod A, Karesen R, Oh DS, Dressler LG, Lonning PE, Strausberg RL, Chanock S, Borresen-Dale AL, Perou CM: Mutation of GATA3 in human breast tumors. Oncogene 2004, 23:7669-7678.
57. Guillard S, Clarke PA, Te PR, Mohri Z, Bjerke L, Valenti M, Raynaud F, Eccles SA, Workman P: Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 2009, 8:443-453.
58. van der Vos KE, Coffer PJ: The extending network of FOXO transcriptional target genes. Antioxid Redox Signal 2011, 14:579-592.
59. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Cajal S, Schwartz S Jr, Vivancos A, Espin E, Rojas S, Baselga J, Tabernero J, Munoz A, Palmer HG: Beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012, 18:892-901.
60. Rosso M, Lapyckyj L, Amiano N, Besso MJ, Sanchez M, Chuluyan E, Vazquez-Levin MH: Secretory leukocyte protease inhibitor (SLPI) expression downregulates E-cadherin, induces beta-catenin re-localisation and triggers apoptosis-related events in breast cancer cells. Biol Cell 2014, 106:308-322.
61. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM, Medema RH: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002, 22:7842-7852.
62. Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoey R, Pylayeva Y, Giancotti F, Blobe GC, Alahari SK: Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst 2011, 103:1513-1528.
63. Hill R, Cautain B, De PN, Link W: Targeting nucleocytoplasmic transport in cancer therapy. Oncotarget 2014, 5:11-28.